Document is current
Any future updates will be listed below
-
Authors
Magen, Assaf http://orcid.org/0000-0001-5473-274X
Hamon, Pauline
Fiaschi, Nathalie
Soong, Brian Y.
Park, Matthew D.
Mattiuz, Raphaël http://orcid.org/0000-0002-3292-1635
Humblin, Etienne
Troncoso, Leanna http://orcid.org/0000-0003-2529-9267
D’souza, Darwin
Dawson, Travis http://orcid.org/0000-0002-9609-793X
Kim, Joel
Hamel, Steven
Buckup, Mark
Chang, Christie
Tabachnikova, Alexandra
Schwartz, Hara
Malissen, Nausicaa
Lavin, Yonit
Soares-Schanoski, Alessandra
Giotti, Bruno
Hegde, Samarth
Ioannou, Giorgio
Gonzalez-Kozlova, Edgar http://orcid.org/0000-0002-6948-0626
Hennequin, Clotilde
Le Berichel, Jessica
Zhao, Zhen
Ward, Stephen C.
Fiel, Isabel
Kou, Baijun
Dobosz, Michael
Li, Lianjie
Adler, Christina
Ni, Min
Wei, Yi
Wang, Wei
Atwal, Gurinder S.
Kundu, Kunal
Cygan, Kamil J. http://orcid.org/0000-0003-2088-474X
Tsankov, Alexander M.
Rahman, Adeeb
Price, Colles
Fernandez, Nicolas
He, Jiang
Gupta, Namita T. http://orcid.org/0000-0002-4517-1546
Kim-Schulze, Seunghee
Gnjatic, Sacha http://orcid.org/0000-0001-5643-9520
Kenigsberg, Ephraim http://orcid.org/0000-0002-4107-3295
Deering, Raquel P.
Schwartz, Myron http://orcid.org/0000-0002-9113-886X
Marron, Thomas U. http://orcid.org/0000-0001-5903-8191
Thurston, Gavin http://orcid.org/0000-0002-4105-5919
Kamphorst, Alice O.
Merad, Miriam http://orcid.org/0000-0002-4481-7827
- License Information
-
More Information
Article History
Received: 9 June 2022
Accepted: 10 April 2023
First Online: 15 June 2023
Competing interests
: M.M. serves on the scientific advisory board and holds stock from Compugen Inc., Myeloid Therapeutics Inc., Morphic Therapeutic Inc., Asher Bio Inc., Dren Bio Inc., Nirogy Inc., Oncoresponse Inc., Owkin Inc., DEMBIO and Larkspur Inc. M.M. serves on the scientific advisory board of Innate Pharma Inc., DBV Inc., Pionyr Inc., OSE Inc. and Genenta Inc. M.M. receives funding for contracted research from Regeneron Inc. and Boerhinger Ingelheim Inc. S.G. reports past consultancy or advisory roles for Merck and OncoMed; research funding from Regeneron Pharmaceuticals related to the current study, and research funding from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, EMD Serono, Pfizer and Takeda, unrelated to the current work. S.G. is a named coinventor on an issued patent (US20190120845A1) for multiplex immunohistochemistry to characterize tumors and treatment responses. The technology is filed through Icahn School of Medicine at Mount Sinai (ISMMS) and is currently unlicensed. This technology was used to evaluate tissue in this study and the results could impact the value of this technology. N. Fiaschi, B.K., M.D., L.L., C.A., M.N., Y.W., W.W., N.T.G., G.S.A., K.K., K.J.C., R.P.D. and G.T. are employees and shareholders of Regeneron Pharmaceuticals Inc. C.P., N. Fernandez and J.H. are employees and shareholders of Vizgen Inc. The remaining authors declare no competing interests.
